Key Highlights

● Fabrice Chouraqui stepped down as Pharming's Chief Executive Officer and Executive Director, effective immediately, a Form 6-K says.

● The release says the Board and Mr. Chouraqui concluded their views on advancing the company's strategy were not sufficiently aligned.

● Chief Commercial Officer Leverne Marsh and Chief Financial Officer Kenneth Lynard were appointed interim co-CEOs, effective immediately.

● Ms. Marsh will lead patient-focused operations and Mr. Lynard global corporate functions while the Board searches for a permanent successor.

Pharming Group N.V. (NASDAQ:PHAR) furnished a Form 6-K to the U.S. Securities and Exchange Commission on September 29, 2026 announcing that Fabrice Chouraqui has stepped down as Chief Executive Officer and Executive Director, effective immediately. Two executives, Chief Commercial Officer Leverne Marsh and Chief Financial Officer Kenneth Lynard, have been appointed interim co-CEOs while the Board conducts a search for a permanent chief executive. The 6-K consists of a company press release titled "Pharming announces CEO transition."

The Departure

The press release says Mr. Chouraqui is leaving after the Board and he concluded that their views on advancing the company's strategy were not sufficiently aligned. It describes the transition as one on which the Board and Mr. Chouraqui agreed. The release does not describe the specific strategic questions involved, does not give any financial terms of the departure, and does not say whether Mr. Chouraqui will remain in any advisory role. It states that the change is effective immediately, so no notice period is described.

Mr. Chouraqui is quoted in the release as saying: "It has been a privilege to lead Pharming and to work alongside colleagues who are deeply committed to improving the lives of people with rare diseases."

The Interim Co-CEOs and the Search

Under the arrangement described in the release, Ms. Marsh, the Chief Commercial Officer, will lead the company's patient-focused operations, and Mr. Lynard, the Chief Financial Officer, will lead its global corporate functions. Both appointments are effective immediately. The release does not provide biographical details for either executive, and it does not say whether either will be a candidate for the permanent role or whether their compensation changes while they serve in the interim positions.

A co-CEO structure divides day-to-day leadership between two executives rather than placing it with one. The release frames the split by function, with one executive covering the patient-facing side of the business and the other covering corporate functions. It does not give a target date for ending the interim arrangement.

Richard Peters, the Board Chairman, is quoted as saying: "Our immediate priority is to ensure continuity across leadership, while maintaining focus on the continued execution of Pharming's strategy and its commitment to patients." The release says the Board has started a formal search for a permanent successor, but it does not name a search firm, describe the profile being sought or set a timeline.

About the Company and What the Release Omits

The release describes Pharming Group N.V. as a global biotechnology company developing and commercializing medicines for rare immune and genetic diseases. It lists the company's shares on Euronext Amsterdam under the symbol PHARM and on Nasdaq under the symbol PHAR. Because Pharming files as a foreign private issuer, it reports such news to the SEC on Form 6-K instead of the Form 8-K used by U.S. domestic companies, and the 6-K does not carry the item-by-item disclosure structure of an 8-K. The media contact listed is Saskia Mehring, Head of Corporate Communications.

The release does not include financial results, guidance or any update on products, clinical programs or commercial performance. It does not say how the leadership change affects any previously announced plans. The release makes no statement about those subjects.

Pharming's Search Beyond the Interim Co-CEOs

The main development to follow is the Board's search for a permanent Chief Executive Officer, which the release says has begun. No date for an appointment is stated in the filing.